Chuanhu anti-gout mixture in therapy of acute gouty arthritis

Chuanhu anti-gout mixture versus Colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN65219941

Enrollment

176

Registered

2013-08-08

Start date

2011-11-01

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute gouty arthritis Musculoskeletal Diseases Gout

Interventions

Following screening, eligible patients were randomized (1:1) to two groups: 1. Chuanhu group, to receive Chuanhu anti-gout mixture 250ml orally daily and placebo (looks like colchicine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults >=18 year old, either sex, with a new clinical diagnosis of gout according to the 1977 American College of Rheumatology classification criteria and onset of the disease duration less than 48 hours were eligible to participate.

Exclusion criteria

Exclusion criteria: 1. Secondary gout, such as rheumatoid arthritis, septic arthritis, traumatic arthritis, etc 2. Gout in intermittent period or with tophi 3. Taking the following drugs: diuretics, pyrazinamide, aspirin, etc 4. Pregnancy, breast-feeding women 5. Cardiovascular and cerebral vascular disease, and severe trauma or underwent surgery 6. Severe infections 7. Hepatobiliary disease or whose ALT and AST were two times higher than upper limit of normal 8. The serum creatinine greater than the upper limit of normal 9. Severe chronic gastrointestinal disease 10. Hematological diseases or endocrine system diseases 11. Undergoing cancer treatment 12. Receiving steroid therapy 13. Allergic to those known ingredients in Chuanhu anti-gout mixture.

Design outcomes

Primary

Measure	Time frame
The recurrence rate within three months of these selected patients after 10 days? treatment	—

Secondary

Measure	Time frame
1. The changes of white blood cells and C-reactive protein (CRP). White blood cells were measured at North West University Nutrition laboratory using an AcT 5diff Cap Pierce Hematology Analyzer, and CRP was measured by immunoturbidimetric test, at the baseline and after 10days of follow up. 2. Adverse reactions, the score of pain, swelling, and activity limitation of the joint (1-4 point scale, for absent, mild, moderate, or severe, respectively), were recorded in the patient diary, and biochemical indicators were detected.	—

Measure

Time frame

1. The changes of white blood cells and C-reactive protein (CRP). White blood cells were measured at North West University Nutrition laboratory using an AcT 5diff Cap Pierce Hematology Analyzer, and CRP was measured by immunoturbidimetric test, at the baseline and after 10days of follow up. 2. Adverse reactions, the score of pain, swelling, and activity limitation of the joint (1-4 point scale, for absent, mild, moderate, or severe, respectively), were recorded in the patient diary, and biochemical indicators were detected.

—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 20, 2026